Analysts Set Generate Biomedicines Inc (NASDAQ:GENB) Target Price at $25.40

Shares of Generate Biomedicines Inc (NASDAQ:GENB) have received a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $25.40.

Several research analysts have recently weighed in on GENB shares. Guggenheim started coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $30.00 price target on the stock. Morgan Stanley lifted their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Finally, The Goldman Sachs Group started coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target on the stock.

Generate Biomedicines Stock Down 4.3%

NASDAQ:GENB opened at $12.38 on Friday. Generate Biomedicines has a 12 month low of $11.00 and a 12 month high of $16.75. The stock has a 50 day moving average of $13.25.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.